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Glomerular and vascular tissues do not down-regulate nitric
oxide synthesis during protracted endotoxemia
DOMINGO DEL CASTILLO, ANUPAM AGARWAL, EDGAR A. JAIMES, and LEOPOLDO RAU
NephroloyIHypertension, Veterans Affairs Medical Center and University of Minnesota Medical School, Minneapolis, Minnesota, USA
Glomerular and vascular tissues do not down-regulate nitric oxide
synthesis during protracted endotoxemia. Down-regulation of cytokines is
implicated as an important component of the phenomenon of tolerance to
bacterial products in humans and animals. Since many effects of endotoxin
and cytokines are mediated by nitric oxide, this study was designed to
evaluate in vivo the L-arginine:NO pathway in endotoxin tolerance.
Sublethal injections of E. coli lipopolysaccharide (LPS, 1 mg/kg body wt,
i.p.) were given to rats daily for five days. Blood levels of N02/N03,
stable metabolites of nitric oxide (NO), significantly increased on day 1
(baseline, 89.64 40, day 1, 260.32 36 nmol/ml; P < 0.05) but returned
to baseline levels on day 5 (77.60 5 nmol/ml). However, urinary
NO2/NO3 remained significantly elevated several-fold throughout the
study period (baseline, 121.25 11.4, day 1,899.35 15.8, day 5, 250.23
21.4 nmol/hr/l00 g body wt). Glomeruli and aortae obtained from these
rats showed increased NO production that was maintained at similar levels
even at day 5 (glomeruli: control, 0.01 0.0, day 1, 22.4 0.3, and day 5,
22.0 2.5, P < 0.05 vs. control; aortae: control, 0.01 0.0, day 1, 4.3
2.2, and day 5, 5.4 1.0 nmol/hr/mg protein, P < 0.05 vs. control,
respectively); this further increased significantly in response to in Vitro LPS
challenge. However, peritoneal macrophages, liver and spleen showed an
initial increase in NO production that decreased significantly by the fifth
day of LPS and could not be further stimulated by in vitro LPS challenge.
Thus, in vivo NO synthesis is down-regulated during protracted LPS. Our
results show that the process is relatively specific to the liver, spleen and
macrophages, and is qualitatively and quantitatively different in vascular
tissues such as aortae and glomeruli.
Clinical and experimental studies have shown that bacterial
products such as endotoxin lipopolysaccharide (LPS) evoke a
wide variety of host responses including inflammation and the
sepsis syndrome. Tumor necrosis factor-a (TNF-a), IL-i, IL-6 as
well as other cytokines have been implicated as mediators of the
host response. Development of tolerance to LPS appears to be an
important mechanism for mitigating the consequences of inflam-
mation and/or sepsis. Down-regulation of proinflammatory cyto-
kines is an important component of the phenomenon of tolerance
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in humans and animals [1—41. Recent studies have established a
relationship between LPS, several cytokines and nitric oxide.
Nitric oxide (NO) results from the conversion of L-arginine to
L-citrulline and NO by the enzyme nitric oxide synthase (NOS) [5,
6]. The biological effects of NO in vivo depend upon the quantity
of NO released and the sensitivity of the involved tissues to NO or
NO by-products. Small (picomolar) quantities of NO released by
constitutive endothelial NO synthase (cNOS) relax the underlying
vascular smooth muscle (VSM) and contribute to the regulation
of vascular tone [6, 7]. NO-mediated vasodilation is dependent on
the activation of soluble guanylate cyclase and intracellular accu-
mulation of cyclic guanosine monophosphate (cGMP) [6, 8, 9], as
well as on direct NO activation of calcium-dependent potassium
channels in VSM [10]. NO-mediated changes in cGMP are also
known to affect leukocyte and platelet function [6, 11, 12].
Induction of NOS (iNOS) by cytokines and/or LPS in a variety of
cells including macrophages [5, 13, 14], hepatocytes [15], VSM
cells [6] and mesangial cells [16] results in the synthesis of NO in
large (nanomolar) quantities. These effects of NO have been
shown to play a role in immune mediated inflammation [14, 17,
18], and are an important component of the nonspecific anti-
bacterial and cytotoxic effects of activated macrophages [19].
NO production by iNOS in VSM cells has been implicated to be
crucial in mediating the vasopressor-resistant hypotension of
septic shock [6, 20, 21]. In addition, large quantities of NO may
induce cellular injury due either to formation of reactive radical
species such as peroxynitrite or to nitrosylation of Fe-S groups in
enzymes required for the respiratory cycle or DNA synthesis [22,
23]. The noxious effects of large quantities of NO are nonspecific.
Thus, induction of NOS in a variety of cells must be tightly
regulated by agents that promote production of NO [24, 25] and
agents such as TGF-j3 and IL-4 that inhibit production [26]. In
vivo, a decline in tissue sensitivity to NO and/or down-regulation
of NO synthesis despite persistent stimulation may be important
(a) in areas of localized inflammation [17, 18] for containment of
tissue injury, and (b) in sepsis, for preventing the irreversibility of
the hemodynamic and systemic changes mediated by NO [4, 6,
27—31]. We therefore sought to examine during protracted LPS
administration to rats whether there is in vivo down-regulation of
NO synthesis. For this purpose we studied the relationship
between NO synthesis, changes in cGMP, the second messenger
of NO, and TNF-a, a cytokine critical in mediating many of the
systemic and local responses to sepsis including synthesis of NO
[4, 25, 30—32]. In addition, we examined with particular attention
whether macrophages and macrophage rich tissues (liver and
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spleen) and vascular tissues (aortae and glomeruli) obtained from
rats that received prolonged LPS in vivo, manifest quantitatively
and qualitatively similar down-regulation of NO synthesis and
decreased responsiveness to cx vivo exposure to LPS.
METHODS
Male Sprague-Dawley rats (275 to 300 g; Harlan Sprague
Dawley Inc., Indianapolis, IN, USA) were used for all experi-
ments. They were housed in air-conditioned rooms (60% relative
humidity, 22°C) with a 12-hour light-dark cycle.
In vivo experiments
Two groups of eight rats were studied. The rats were placed in
metabolic cages 24 hours prior to the baseline studies and
remained in these cages until the end of the study. Rats were pair
fed on a daily basis with free access to water. In all rats, baseline
studies included 24-hour urine collections and blood samples
obtained at the end of the urine collection by means of a tail
incision.
Group I. The rats in this group received LPS 48 hours after the
baseline studies. The dosage was 1 mg/kg in 0.3 cc of sterile
phosphate-buffered saline (PBS) intraperitoneally (i.p.) daily for
five consecutive days and then stopped [30]. The rats remained in
the metabolic cages with no further LPS treatment for 48 hours,
after which time another dose of LPS was given. Tail blood
samples were obtained 24 hours after the first, fifth, and last
doses of LPS; 24-hour urine collections were obtained daily.
N02/NO3 levels were measured in blood and urine samples.
Group II (control group). The rats in this group were subjected
to the same protocol as the Group I rats, but instead of LPS they
received just the 0.3 cc of PBS i.p.
An additional group of six rats were treated with LPS as in
group I, but in order to determine peak serum TNF-a levels blood
samples were obtained at baseline as well as one hour after the
first and fifth doses of LPS [4, 32].
Ex vivo experiments
In addition to the above studies, to measure cx vivo NO and
cGMP production by different tissues, three more groups of rats
(N = 18 in each group) were studied. The first group (Group A)
comprised of rats that received PBS (control group), and the
second and third groups (Groups B and C) received LPS and were
sacrificed six hours after the second dose of LPS (on day 2) and six
hours after the fifth dose of LPS (on day 5), respectively (Fig. 1).
Urinary N027N03 was measured daily for five days in the third
group (Group C) (as in Group I above), to further confirm our
observations on the kinetics of NO2 7N03 production in endo-
toxin tolerance. The results reported are the mean of these
experiments (Fig. 1).
Tissue studies
For these studies, each rat was first anesthetized with mactin
(100 mg/kg i.p.). Then, using sterile techniques, a midline incision
was made, the abdominal aorta was exposed, and the rat was
sacrificed by exsanguination [27]. The liver, spleen, kidneys, and
thoracic aorta were removed. The thoracic aorta from each rat
was washed with sterile PBS, cleaned of fascia, and cut into 4 mm
segments, using care not to damage the endothelium. Glomeruli
were isolated using a series of nylon sieves as described elsewhere
[27]. Liver and spleen were washed with sterile PBS and cut in 2
Experimental design
— Control PBS p 5 days
II — LPS 1 mg/kg body wt i.p. 1 day
Ill — LPS 1 mg/kg body wt p. 5 days
Sacrifice/ \
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Pooled tissue
Assay for NO/NO and/or cGMP
Fig. 1. Schematic representation of the experimental protocols.
m slices. The livers, spleens, thoracic aortae, and glomeruli were
pooled from all the rats in each group and placed in Eagle's MEM
without phenol red, supplemented with L-arginine (final concen-
tration = 2 mM) and 10% fetal calf serum. The tissue pools from
each group were then divided into two aliquots; LPS (10 xg/ml)
was added to one of the aliquots. All the tissues were incubated at
37°C in 5% C02/95% room air for 18 to 20 hours (Fig. 1). At the
end of this time, the medium was removed and frozen at —20°C
until it was assayed in duplicate for NO27NO1. Background
NO2/NO3 - levels in media not exposed to tissues were sub-
tracted from the sample results which were then factored for the
weight of the tissue in each dish.
Three additional pools of glomeruli and aortae were incubated
with either: (1) a specific inhibitor of NO synthesis, L-NMMA
(1 mM), in the presence of 0.6 ms L-arginine in the media; (2) an
inhibitor of the induction of NO synthase, dexamethasone
(0.1 mM) [33]; or (3) an inhibitor of protein synthesis, cyclohexi-
mide (1 mM) [19, 33]. Determination of glomerular cGMP was
done according to techniques described below.
Peritoneal macrophages studies
Peritoneal cells were obtained by lavage with 25 ml of sterile
PBS in three additional groups of six rats that received i.p. PBS or
LPS for one day or five days using the same protocol described
previously. The peritoneal exudate cells were centrifuged at 200 )<
g and washed with media Eagle's MEM supplemented with 2 msi
L-arginine and 10% fetal calf serum and then resuspended in this
media at a concentration of 4 to 10 x 106 cells/mI in 24-well dishes
(Costar Corp., Cambridge, MA, USA). Viability was greater than
95%, as determined by trypan blue dye exclusion. The cells were
incubated for 1.5 hours at 37°C in 5% CO2/95% air to allow
macrophages to adhere to the plates. The cells were then washed
twice with warm PBS to remove the nonadherent cells, after which
medium alone or medium plus LPS (10 mg/mI) was added to the
adherent monolayers and incubated for 18 to 20 hours [34]. The
cell protein remaining in each well was dissolved overnight in 1%
Glomeruli
(Pooled)
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sodium dodecyl sulfate and measured by the method of Lowry et
a! as described previously [16].
N021N03 assay
Serum and urine samples, as well as the media from the ex vivo
tissue incubation were assayed for the stable end products of NO,
N02, and N03. As described elsewhere [16, 27],samples were
first incubated with Escherichia coli nitrate reductase to convert
the N03 in samples to N02. The total N02 in the samples
(representing both N02 and the reduced NO3—) was measured
using the Griess reagent. Known concentrations of NaNO2 and
NaNO3 were used as standards in each assay. The quantity of
NO2/NO was expressed as nanomolar concentration.
NOS enzyme activity
We also measured NOS enzyme activity in glomerular homog-
enates by the conversion of [14C] L-arginine (Amersham, Arling-
ton Heights, IL, USA) to ['4C] L-citrulline. Briefly, glomeruli
were isolated using the sieving technique as previously described
[16], suspended in homogenization buffer (TRIS 50 mM, mercap-
toethanol 0.1 mtvi, EDTA 0.1 mivi, EGTA 0.1 mrvi, leupeptin 2 jLM,
pepstatin A 1 xM, PMSF 1 mrvi, pH 7.4), and sonicated three times
(15 seconds pulses). Forty microliters of this sample were added
to 100 pi of assay buffer (KH2PO4 50 mM, MgCl2 1 mad, CaC12 1
mM, Valine 50 mtvi, L-citrulline 1 mivi, L-arginine 20 .tM, dithio-
trietol 1 mi, NADPH 2 mrvi, BH4 3 tM, FAD 3 j.LM, FMN 3 pM,
0.5 xCi/m1 ['4C] L-arginine) and incubated for 20 minutes at 37°C.
The reaction was stopped with the addition of 500 jil of ice cold
buffer (HEPES 20 mM, EDTA 2 mri, EGTA 2 mM, pH 5.5). To
separate [14C] L-arginine from ['4C] L-citrulline, samples were
loaded onto 1 ml columns of Dowex resin (AG5OWX-8 Na form),
and eluted with 500 pA of distilled water. Aliquots were used for
liquid scintillation counting. Ca-dependent activity was deter-
mined as the difference between the ['4C] L-citrulline produced
from control samples and samples containing EGTA 3 mM to bind
calcium. Calcium independent activity was determined as the
difference between samples containing 3 mM EGTA and samples
containing both EGTA 3 mM and 1 mivi L-nitroarginine, an
inhibitor of NOS. NOS activity was expressed as pmol/mg of tissue
protein/mm of [14C] L-citrulline.
cGMP assay
An enzyme immunoassay was used for the determination of
cGMP in the plasma, urine and supernatants from the ex vivo
incubations (Amersham-EIA RPN226). Intracellular levels of
cGMP were measured in glomeruli as described elsewhere [9, 16].
Briefly, 0,1 m'vi IBMX was added at the beginning of the study.
After the incubation period the medium was removed and cGMP
extracted with 0.1 N HC1 for one hour. Samples were frozen at
—20°C until the assay was performed. The final result is the sum
of both values. The amount of cGMP from each well was factored
for the amount of tissue weight in the well.
Assay for TNF-a
TNF-cx was quantitated by assessing the extent of killing of the
TNF-a-sensitive cell line L929 [4, 35]. Briefly, serum samples from
the animals were added to the L929 cells cultured in 96-wellplates
and were then pretreated with 2 tg/ml of actinomycin D and
incubated overnight at 37°C in a humidified 5% CO2 incubator.
The amount of TNF-a required to lyse 50% of the L929 cells in
the assay defined 1 U of TNF-a activity.
Statistics
All values are expressed as the mean SEM. Results were
analyzed by comparing the experimental data using ANOVA. For
multiple comparisons within a group, the Newman-Keuls test was
used. Where appropriate, a Student's t-test was used to test the
differences between groups. A P value of <0.05 was considered to
be significant.
RESULTS
In vivo experiments
Food intake. Control and experimental rats were pair fed. After
the first dose of LPS, the rats appeared sick. Food intake
decreased by about 90% during the first two days and then
progressively increased; by the fifth day rats ate the same amount
of food as during the baseline studies. A decrease in body wt was
observed during the first two days following LPS administration,
but the weight progressively increased thereafter (baseline, 267
8.0 g; day 1, 254 lOg; day 2, 237 13 g; day 3, 244 17 g; day
5, 260 6 g; P = NS).
In vivo production of NO is down-regulated after protracted
endotoxemia
After the administration of the first dose of LPS, blood levels of
NO2 /N03 increased from 90 4 to 260 36 nmol/ml (P <
0.05). However, despite daily administration of the same LPS
dose, blood levels of NO2 /N03 at dayS were similar to those at
baseline (Fig. 2 and Table 1). Urinary NO27NO3 excretion
remained constant throughout the study in control rats, whereas a
significant rise in urinary NO2 /NO3 was observed in LPS-
treated rats (Fig. 2 and Table 1). One day after LPS administra-
tion, the urinary N02/N03 excretion increased more than
sevenfold above baseline levels and progressively decreased there-
after until the fifth day, when LPS administration was stopped.
Urinary N02/NO3 on the fifth day remained more than twofold
elevated. After day 5, N027N03 remained constant and did not
increase even after LPS administration on day 8. Thus, although
blood levels at day 5 were comparable to baseline, urinary
excretion NO2/NO3 remained elevated by twofold. Urinary
cGMP increased significantly after the first dose of LPS (baseline,
253 25 and day 1, 821 131 pmollhr/100 g body wt) and
remained high until day 5 of treatment (Table 1). However, blood
levels of cGMP returned to baseline levels at day 5. These data
demonstrate that although blood levels of cGMP and NO2 /
N03 returned to baseline levels at day 5, the urinary excretion of
NO2 /N03 and cGMP remained elevated by two- and fourfold,
respectively.
NOS enzyme activity
To further corroborate that the persistent increase in urinary
excretion of NO2 /N03 originated in the kidney, we determined
NOS enzyme activity in glomeruli from kidneys of rats with
endotoxin tolerance and from control rats. The NOS activity
measured in glomeruli from rats subjected to LPS for one day and
five days was significantly higher compared to control. Total NOS
activity was 2.34 0.1 pmol/mg/mjn citrulline in control rats, andincreased to 3.2 0.1 pmol/mg/min citrulline after the first dose
Fig. 2. (A) Serum levels of N02/N03 before (baseline) and after
administration of LPS (1 mg/kg i.p.). Blood samples drawn at baseline, 1,
5 and 8 days after LPS. (B) Urinary excretion of NO27NO before and
after administration of either LPS (1 mg/kg i.p.; ) or 0.3 ml of PBS i.p.
(s). Arrows represent the time of the injections of LPS or PBS. < 0.05
versus baseline by ANOVA and Student Newman-Keuls test, #P < 0.05
versus baseline by unpaired t-test.
of LPS and to 3.5 0.2 pmol/mglmin citrulline after 5 doses of
LPS (P < 0.05 vs. control). We further confirmed that such
increased NOS activity was mainly calcium independent at day 1
and day 5 (Table 2). mRNA RT-PCR confirmed an increase in
iNOS in kidneys from rats that received LPS for five days
(A. Gomez, Dept. of Pediatrics, U of Virginia, personal commu-
nication). These results demonstrate that enzyme activity of an
inducible calcium independent NOS is significantly increased in
glomeruli at day 1, and this increases further at day 5 in rats with
endotoxin tolerance.
Serum tumor necrosis factor-a
Similar to the serum levels of N021NO3, serum TNF-a levels
increased significantly after the first dose of LPS (0.26 0.14.vs.
291.81 71.13 UIml,P <0.05) and decreased to 6.76 3.88 U/mI
4 (P = NS vs. baseline) on the fifth day.
Down-regulation of NO synthesis after protracted endotoxin
administration is tissue selective
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The changes in NO2/NO3 observed in vivo could have been
due to changes in the disposition of LPS and/or NO. Hence, the
aim of these studies was to determine whether there was down-
regulation of NO synthesis at the tissue level.
Ex vivo tissue incubation in media without LPS. Hepatic, splenic,
aortic, and glomerular tissues from rats given LPS revealed
induction of NO synthesis. Indeed, compared with control rats,
the N02/N03 concentration was increased several-fold in the
_____________________________________
supernatants of tissue cultures from liver (3-fold), spleen (3-fold),
I aorta (5-fold), and glomeruli (20-fold), obtained from rats given
Baseline 1 2 3 4 5 6 7 8 LPS one day earlier (Fig. 3 and Table 3). NO synthesis in aortae
Da and glomeruli remained similar on day 5 to that observed on thefirst day after in vivo LPS administration. However, synthesis of
NO by the liver and spleen decreased by 55% and 30%, respec-
B tively, on the fifth day of LPS (Fig. 3 and Table 3).
4, * .1. 1. 1. 4, 1 Ex vivo tissue incubation in media with LPS. NO synthesis in
response to LPS added ex vivo to the tissues in culture was
dependent upon prior exposure to LPS and the duration of
exposure. Tissues from control rats and from rats given LPS for
only one day in vivo showed a robust increase in the rate of NO
* synthesis to the ev vivo challenge (Fig. 3). On the other hand,
while the liver and spleen from rats given LPS for five days failed
to further increase NO synthesis, the aortae and glomeruli of
these rats showed significantly augmented NO synthesis in re-
sponse to the ex vivo LPS challenge (Fig. 3). Neither dexametha-
sone nor cycloheximide affected the basal production of NO by
aortae and glomeruli, but both blunted any further increase in NO
synthesis in response to LPS added in vitro. These findings suggest
• 1j that the latter may be dependent upon induction of new iNOS
B un 1 7 8 (Fig. 4). L-NMMA in the presence of 0.6 mM L-arginine in thease e
culture media resulted in inhibition of basal as well as LPS-
Days stimulated release of NO2 /N03 to the supernatant (data not
shown).
Compared with control rats, the concentration of cGMP in
preparations of pooled glomeruli obtained from rats (N = 6) one
day after the first dose of LPS was increased (295 vs. 7 fmol/24
hr/mg tissue wt) and remained high in rats (N = 6) sacrificed after
five days of LPS (444 fmol/24 hr/mg tissue weight). Moreover,
cGMP production further increased by 40% in response to LPS
added ex vivo to glomeruli from rats sacrificed after five days of
LPS (data not shown). Therefore, vascular tissues (aortae and
glomeruli) showed no down-regulation of NO synthesis, whereas
liver and spleen did show down-regulation of NO synthesis as well
as "tolerance" to further LPS challenge.
2 3 4 5 6
Macrophages
Similar to liver and spleen, peritoneal macrophages from
animals (N = 4) sacrificed one day after the first dose of LPS
produced significantly more N02/N01 during the ex vivo
incubation than those obtained from either control (N = 7) or
experimental rats (N = 7) sacrificed after five days of LPS (3.9
0.30 vs. 0.10 0.09 and 1.6 0.20 nmol/24 hr/mg protein
respectively, P < 0.05; Fig. 5). Thus, macrophages harvested from
rats after the fifth day of LPS treatment produced 60% less
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Table 1. Urinary and plasma levels of N02/N03 and cGMP during protracted endotoxemia
Day
Urinary N021N03
nmol/hrIlOO gm BW
Urinary cGMP
pmol/hr/100 gm BW
Plasma NO2/NO3
nmollml
Plasma cGMP
pmol/ml
Basal 121.25 11.4 253.0 25.0 89.64 40.0 25.5 3.0
Day 1 899.35 150.8a 821.0 131.Oa 260.32 36.Oa 34.2 4.o
Day 5 250.23 2l.4' 822.0 144.Oa 77.60 5.0 18.9 3.0
P < 0.05 vs baseline by ANOVA and student Newman-Keuls test.
'P < 0.05 vs baseline by unpaired t test.
N = 8.
,J)
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0
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Media Media + LPS
Liver Spleen
Fig. 3. Production of N02/N03 by pooled aortae, glomeruli, liver and
spleen from groups of rats sacrificed after LPS administration (1 mg/kg
i.p.) for either one day (E) or five days (B). Symbol (U) is PBS control
group. < 0.05, LPS versus control by ANOVA and Student Newman-
Keuls test. Tissues were incubated cv vivo for 20 hours in media alone or
media containing LPS (10 gIml). #P < 0.05 vs tissue incubated in media
alone without LPS.
Table 2. Glomerular NOS enzyme activity in protracted endotoxemia
(pmol/mglmin)
Total
Ca
dependent
Cail
independent
Control 2.34 0.1 2.34 0.1 0.0
Day 1 3.21 0.1k' 1.26 0.1 1.94 0.la
Day 5 3.51 0.2 1.09 0.1 2.41 0.2
A
a P < 0.05 vs control by ANOVA (N = 3).
Table 3. Ex-vivo N02/N03 production during protracted endotoxemia
#
Tissue Control LPS day 1 LPS day 5
Liver 4.7 1.5 13.0 0.4a 7.1 2.8
Spleen 9.7 4.7 24.5 0.3 17.4 4.0
Glomeruli 0.01 0.0 22.4 0.3a 22.0 2.5a
Thoracic aorta 0.01 0.0 4.3 2.2a 5.4 1.Oa
Media Media + LPS
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a P < 0.05 vs control by ANOVA and student Newman—Keuls test.
N02/N03 than macrophages obtained from rats sacrificed one
day after the first dose of LPS. However, different from liver and
spleen, addition of LPS to the incubation media of macrophages
obtained 24 hours after the first dose of LPS elicited a modest
increase in N027N03 similar to the response observed in
macrophages obtained from rats after the fifth day of (3.9 0.3 vs.
5.5 1.53,P = 0.057, and 1.6 0.22 vs. 2.03 0.83 nmol!24 hr/sag
protein respectively, P = 0.22; Fig. 5).
DISCUSSION
We have shown that during protracted endotoxemia there is
concomitant down-regulation of TNF-a and NO synthesis. In
response to daily administration of LPS, rats developed an initial
increase in both serum TNF-cs and N02/N03, the stable
oxidation end-products of NO, followed by a return to baseline
levels by the fifth day and thereafter. Changes in urinary NO2—!
NO3- should have mirrored those observed in blood, but re-
mained elevated several-fold above baseline. We, therefore, stud-
ied cv vivo peritoneal macrophages, liver, spleen, aorta and
glomeruli from these rats. In these studies we found that all
tissues, including peritoneal macrophages, obtained from rats one
day after receiving LPS showed high N02/N03 production.
However, after five days of LPS, high levels of NO synthesis were
observed only in the aorta and glomeruli, while in spleen, liver,
and macrophages, the levels were significantly decreased. The
observation of high urinary levels of N021N03 at day 5, while
blood levels are decreased, suggest that the source of this increase
#
*
#
*
Media Media + LPS
is possibly the kidney, and this is further confirmed by our findings
of persistent production of NO from isolated glomeruli.
The activity of NOS extracted from glomerular homogenates,
cQ)o .z
-S.z
ti)
C'..
OE
Fig. 5. Production of N02/N03 by
peritoneal macrophages from groups of rats
sacrificed after PBS (U, control) or LPS
administration (1 mg/kg i.p.) for either one day
(LII) or five days (n). Animals were sacrificed
six hours after PBS or LPS administration.
Macrophages were incubated for 24 hours in
media alone or in media with LPS (10 j.tg/ml).
< 0.05 versus control and versus day 5, by
ANOVA and Student Newman-Keuls test.
#P < 0.05 between macrophages incubated
with or without LPS.
obtained from rats after either the first or fifth day of LPS
administration, was increased (37% and 52.4% change) compared
with that observed in glomeruli from control rats. The NOS
activity was calcium independent (not inhibitable by EGTA); this
suggests that high NO production by these tissues originated from
iNOS. RT-PCR analysis confirmed that LPS administration in-
duced iNOS mRNA in kidneys obtained from rats after the fifth
day of LPS. To determine whether the differences in NO produc-
tion were due to disparate degrees of "tolerance" to LPS achieved
by the different tissues, we performed further LPS challenges in
vitro. In these studies we found distinct, tissue selective responses
to persistent LPS stimulation. Indeed, after the initial in vivo dose
of LPS, all tissues studied were capable of further increasing NO
synthesis when exposed to LPS in vitro. However, by the fifth day,
tolerance to LPS had developed. This was tissue-selective, since
the aorta and glomeruli but not spleen, liver, or peritoneal
macrophages responded to LPS with an increase of N027N03
release into the supernatant. Moreover, cGMP levels were signif-
icantly increased in glomeruli obtained from rats after one day as
well as after five days of in vivo LPS administration, compared
with control rats, and they further increased in response to the ex
vivo LPS dose.
L-NMMA, an inhibitor of NO synthesis, significantly inhibited
in vitro NO production by all tissues studied, independently of
140
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A Glomeruli B Aortae
Fig. 4. Effect of dexamethasone and
cycloheximide on the production of N02/N03
induced by LPS added to the media. Data are
from pooled glomeruli and aortae obtained
from groups of rats that received LPS i.p. for
one day (fl) or five days (; N = 6 in each
group). Abbreviations are: Dexa,
LPS + dexamethasone 0.1 mM; CH, cycloheximide 1
CH mM.
LPS LPS+ LPS+ LPS LPS+
Dexa CH Dexa
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whether LPS was given only in vivo or both in vivo arid in vitro. On
the other hand, dexamethasone [6, 35], an inhibitor of the
induction of NOS, and cycloheximide [6, 33], an inhibitor of
protein synthesis, prevented the increase in NO synthesis in
response to only the in vitro LPS dose. Thus, increased NO
synthesis in response to ex vivo LPS by the nontolerant tissues may
be dependent predominately upon de novo synthesis of additional
iNOS [6, 33].
The reasons for the differences in the responses among the
various tissues are at present unclear. There are multiple potential
sites in the NO-synthesis cascade at which either stimulatory or
inhibitory mechanisms can act [13, 24, 36]. Cellular NO produc-
tion depends upon NOS activity, L-arginine concentration, and
the availability of several cofactors necessary for NOS enzymatic
activity, as well as the responsiveness of different cells to cytokines
and other stimuli [6, 13, 14, 36, 37]. Important variations in these
regulated steps of NO synthesis in different cell types [40] may
explain the nonuniformity of down-regulation of NO synthesis in
different tissues [41]. The cellular basis of endotoxin tolerance
involves down-regulation of transcriptional and/or translational
events that regulate the rapid response cytokine genes. in vitro
studies at the molecular level suggest that LPS tolerance is not
due to down-regulation of LPS receptors, but involves mobiliza-
tion of the ubiquitous transcription factor, NF-KB, an important
regulator of TNF-cs, IL-I and inducible NOS genes [38, 39].
Prolonged NO generation by the aorta and glomerulus is probably
dependent on cytokines other than TNF-a [40], since TNF-a
levels were decreased at day 5, in our studies. However, in vitro
cellular responses to LPS or isolated cytokines by cells grown in
the absence of their "natural habitat," that is, extracellular matrix,
may not mimic their responses in vivo when located in tissues and
are exposed simultaneously or sequentially to multiple cytokines
capable of interacting with one another [411.
The differences we observed in the tissue selective down-
regulation of NO synthesis may also be due, at least in part, to
differential expression of different isoforms of iNOS in these
tissues. Indeed, recent studies by Mohaupt et al [42] identified two
isoforms of iNOS in the rat kidney, and they also found differen-
tial expression and induction of these isoforms in response to LPS
and cytokines such as TNF-a and IFN-y. These authors reported
that in the LPS treated kidney and in cultured mesangial cells
exposed to TNF-a and IFN-y, the vascular smooth muscle
isoform of iNOS (vsmNOS) was the predominant isoform, rather
than the macrophage iNOS (macNOS), which is the principal
isoform expressed in the basal state in glomeruli and tubules.
The results of our studies have important implications regard-
ing the in vivo role of NO in inflammation [17, 18] and in defense
mechanisms during protracted endotoxemia [19, 28]. Indeed, our
findings suggest that the pro-inflammatory as well as the nonspe-
cific cytotoxic and anti-infectious roles of NO may progressively
decrease over time due to the development of tolerance and NO
synthesis down-regulation, particularly since it affects macro-
phages and organs such as the liver and spleen more prominently.
The lack of similar down-regulation of NO synthesis in vascular
tissues such as the aorta and glomerulus may explain the persis-
tence of hyporesponsiveness to vasopressors during protracted
sepsis [6, 211. We have previously shown, however, that during
endotoxemia the vasodilatory and antithrombogenic actions of
endogenous NO are important in sustaining organ perfusion and
preventing thrombosis in organs such as the kidney [27]. Hence,
this lack of down-regulation of NO synthesis in vascular tissues
may also be beneficial.
Morbidity and mortality in patients with gram-negative endo-
toxemia continue to be high [43]. These studies demonstrate that
there is down-regulation of NO synthesis and TNF-a during
protracted endotoxemia. Particularly novel are the previously
unrecognized findings that down-regulation of NO synthesis in
vivo is tissue selective. The results of our studies may be critical for
understanding the role of NO in the pathophysiology of sepsis and
hopefully for the development of therapeutic strategies aimed at
reducing the high morbidity and mortality which accompany this
syndrome.
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APPENDIX
Abbreviations used in this paper are: NO, nitric oxide; NOS, nitric oxide
synthase; cNOS, constitutive nitric oxide synthase; iNOS, induced nitric
oxide synthase; VSM, vascular smooth muscle; cGMP, cyclic guanosine
monophosphate; LPS, lipopolysaccharide; DNA, deoxyribonucleic acid;
PBS, phosphate-buffered saline; i.p., intraperitoneally; MEM, minimal
essential media; TNF-a, tumor necrosis factor alpha; TGF-3, transform-
ing growth factor /3.
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